The “diabesity” pandemic accounts for a global prevalence of nonalcoholic fatty liver disease (NAFLD) in the diabetic population of about 55.5%, with estimated rates of nonal coholic steatohepatitis (NASH) and advanced liver fibrosis of 37.3% and 4.8%, respectively [1]. Moreover, different lines of evidence showed that type 2 diabetes (T2D) is the main cause of fibrosis progression, cirrhosis development, and Hepatocellular carcinoma (HCC) occurrence...
Petta, S. (2023). Glycemic control, body weight reduction, or glucose-lowering therapy in diabetic patients: What is better for the liver?. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 33(3), 649-650 [10.1016/j.numecd.2022.12.024].
Glycemic control, body weight reduction, or glucose-lowering therapy in diabetic patients: What is better for the liver?
Petta, Salvatore
Primo
2023-03-01
Abstract
The “diabesity” pandemic accounts for a global prevalence of nonalcoholic fatty liver disease (NAFLD) in the diabetic population of about 55.5%, with estimated rates of nonal coholic steatohepatitis (NASH) and advanced liver fibrosis of 37.3% and 4.8%, respectively [1]. Moreover, different lines of evidence showed that type 2 diabetes (T2D) is the main cause of fibrosis progression, cirrhosis development, and Hepatocellular carcinoma (HCC) occurrence...
| File | Dimensione | Formato | |
|---|---|---|---|
|
NMCD-S-22-01618.pdf
accesso aperto
Descrizione: article
Tipologia:
Pre-print
Dimensione
606.46 kB
Formato
Adobe PDF
|
606.46 kB | Adobe PDF | Visualizza/Apri |
|
Glycemic control, body weight reduction, or glucose-lowering therapy in diabetic patients_ What is better for the liver_.pdf
Solo gestori archvio
Descrizione: articolo
Tipologia:
Versione Editoriale
Dimensione
187.05 kB
Formato
Adobe PDF
|
187.05 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
